BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S. Food and Drug Administration (FDA) has granted priority review for a new indication filing of its Tevimbra (tislelizumab) combined with Ziihera (zanidatamab) as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The FDA also awarded zanidatamab breakthrough therapy designation (BTD) for use with chemotherapy in the same indication.

Regulatory Milestones

Drug Profile & Mechanism of Action

Tevimbra (tislelizumab)

• Mechanism: Anti-programmed cell death protein-1 (PD-1) monoclonal antibody
• Approval Status: Approved in multiple regions worldwide across various oncology indications
• Role in Combination: Immune checkpoint inhibition to enhance anti-tumor immune response

Ziihera (zanidatamab)

• Mechanism: Humanized bispecific antibody targeting HER2 with binding to two non-overlapping extracellular epitopes
• Innovation: Dual HER2 binding creates enhanced receptor internalization and anti-tumor activity compared to single-epitope antibodies
• Development Partnership: Originally developed by Zymeworks, now part of BeOne’s strategic portfolio

Clinical Data – HERIZON-GEA-01 Phase III Study

Market Context & Competitive Landscape

Strategic Implications & Commercial Outlook

• Portfolio Synergy: Leverages BeOne’s established PD-1 franchise with novel bispecific antibody innovation
• Regulatory Momentum: Dual designations (priority review + BTD) accelerate path to market approval
• Global Potential: Strong Phase III data supports international regulatory filings beyond U.S. market
• Commercial Infrastructure: BeOne’s existing oncology commercial team can rapidly deploy upon approval
• Standard of Care Disruption: Potential to establish new first-line treatment paradigm for HER2-positive GEA

Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial potential. Actual results may differ due to risks including FDA review outcomes, competitive developments, and market adoption dynamics in the gastrointestinal oncology space.-Fineline Info & Tech